Loss of CHD1 has been implicated in the initiation of ETS prostate cancers, preventing ERG rearrangement in the prostate [56,144] and thus explaining the exclusivity between ETS positivity and homozygous loss of CHD1. The gene discussed is ERG; the disease is prostate cancer.